GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
SMS Pharmaceuticals Ltd

SMS Pharma: Q2 FY27 PAT up 57% to ₹39.57 crore on 30% YoY Revenue Growth

RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 04 Nov 2026, 06:35 PM IST  ·  BSE ID: 4dcc0ec1-6397-47d5-beb0-ad885018fd7a
View Original BSE Filing (PDF)
💡
In Simple Terms
SMS Pharmaceuticals reported strong Q2 FY27 results, with sales up 30% and profits up 57% compared to the same quarter last year.
🤖 AI Summary
  • SMS Pharmaceuticals' Q2 FY27 revenue from operations increased 30% YoY to ₹316.08 crore.
  • Net profit (PAT) for Q2 FY27 surged 57% YoY to ₹39.57 crore, with a 13% PAT margin.
  • Gross margin expanded 268 bps YoY to 35%, reflecting benefits from backward integration.
  • EBITDA margin improved 145 bps YoY to 21% for Q2 FY27, driven by operating leverage.
  • Six DMF/CEP filings completed in FY27 to date; ₹280 crore capex program on track for FY27 completion.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Revenue from operations (Q2 FY27)
₹316.08 crore
30%
PAT (Q2 FY27)
₹39.57 crore
57%
Gross profit margin (Q2 FY27)
35%
268bps
EBITDA margin (Q2 FY27)
21%
145bps
Revenue from operations (H1 FY27)
₹523.05 crore
19%
PAT (H1 FY27)
₹59.76 crore
36%
🏢 How This Affects the Company
📈
Business Impact
Revenue growth was driven by higher volumes and improved price realization, particularly in anti-inflammatory APIs and ARVs. The company expanded its therapeutic portfolio with 6 DMF/CEP filings in FY27 and plans for 6-8 new molecules to commence production in FY28.
💰
Financial Impact
Profitability metrics improved across the board, with gross margin expanding 268 bps YoY to 35% and EBITDA margin increasing 145 bps YoY to 21%, leading to a 57% YoY PAT growth. The ₹280 crore capital expenditure program is on track, with ₹160 crore deployed.
⚙️
Operational Impact
Backward integration and capacity expansion initiatives have contributed to improved margins. The Peptides R&D facility is fully operational, with pilot scale production targeted for Q4 FY27, establishing a new CDMO platform.
⚠️
Risk Impact
The diversification into new molecules and therapeutic areas, alongside backward integration, aims to reduce dependence on specific segments and enhance operational resilience.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this financial results press release.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, which shows significant growth in revenue and profitability for Q2 and H1 FY27.
🔍
Management Signal
Management's statements indicate confidence in exceeding earlier full-year guidance, supported by ongoing investments in capacity, R&D, and backward integration.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q3 FY27 financial results — assess if revenue and profit growth trends continue.
Update on Ibuprofen capex completion and volume ramp-up timeline.
Progress on pilot scale production at SMS Peptides Private Limited in Q4 FY27.
LOW RISK The filing indicates strong financial performance and strategic investments, with no new significant risks identified.
💡 Investor Takeaway
SMS Pharmaceuticals reported Q2 FY27 revenue from operations at ₹316.08 crore, up 30% YoY, and PAT at ₹39.57 crore, up 57% YoY. Gross margin improved to 35% and EBITDA margin to 21%, benefiting from backward integration and operating leverage. The ₹280 crore capex program is 57% deployed.
⚖️ Strengths & Concerns

✅ Positives

  • Q2 FY27 PAT grew 57% YoY to ₹39.57 crore, driven by strong revenue growth and margin expansion.
  • Gross margin expanded 268 bps YoY to 35%, reflecting tangible benefits from backward integration efforts.

⚠️ Concerns

  • H1 FY27 revenue from the anti-diabetic segment declined 39% YoY to ₹64.66 crore.
  • H1 FY27 revenue from the anti-ulcer segment also decreased 39% YoY to ₹14.18 crore.
📅 Company Track Record
SMS Pharmaceuticals previously reported a 55.65% surge in Q2 FY27 net profit to Rs. 3,913.47 Lakhs (as per prior filing's unit) and Q1 FY27 revenue growth of 6% YoY to ₹207.0 Cr with PAT up 8% YoY. This Q2 FY27 filing confirms sustained strong performance.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was SMS Pharmaceuticals' revenue from operations in Q2 FY27?
SMS Pharmaceuticals reported revenue from operations of ₹316.08 crore in Q2 FY27, representing a 30% increase year-over-year.
What was SMS Pharmaceuticals' net profit (PAT) for Q2 FY27?
The net profit (PAT) for SMS Pharmaceuticals in Q2 FY27 was ₹39.57 crore, a 57% increase compared to the same period last year.
How did SMS Pharmaceuticals' EBITDA margin perform in Q2 FY27?
SMS Pharmaceuticals' EBITDA margin expanded by 145 bps YoY to 21% in Q2 FY27, attributed to operating leverage.
What is the status of SMS Pharmaceuticals' capital expenditure program?
The ₹280 crore capital expenditure program is on track for completion by FY27, with ₹160 crore deployed to date.
Which therapeutic segments drove SMS Pharmaceuticals' H1 FY27 revenue growth?
In H1 FY27, Anti Retro Viral (ARV) revenue grew 47% to ₹150.25 crore and Anti-inflammatory revenue grew 25% to ₹110.03 crore, contributing significantly to overall revenue.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.